COST- EFFECTIVENESS ANALYSIS OF PARECOXIB IN THE MANAGEMENT OF POSTSURGICAL PAIN IN MEXICO

Author(s)

Muciño-Ortega E, Galindo-Suárez RMPfizer S.A. de C.V., Mexico City, Mexico

OBJECTIVES: Pain management is an important dimension of postsurgical care. The aim of this study was to determine the cost-effectiveness of parecoxib, morphine, buprenorphine and ketorolac in the management of postsurgical pain, from the perspective of the Mexican Social Security Institute (IMSS). METHODS: A decision-tree model was used to assess the outcomes of parecoxib 40mg; buprenorphine 0.12, 0.18 and 0.36mg; morphine 4, 6 and 12mg and ketorolac 30mg in women who received them in the morning after their gynecologic surgery. In case of failure, rescue therapy with morphine 4mg was allowed. The time horizon is 12 hours after the medication was received. Only the acquisition cost was considered (2011 US$). The effectiveness outcome was the proportion of respondents who experienced onset of analgesia and rated their medication as “good” or “excellent” (through patient´s global evaluation of the study medication questionnaire). Literature review was performed to extract the clinical outcomes of competing alternatives (the doses of morphine 4mg, buprenorphine 0.12mg and so on, were considered equianalgesic). Acquisition costs were extracted from official institutional sources. The results of the analysis are expressed through the ICER (ketorolac as basecase). Univariate sensitivity analysis was performed. RESULTS: The proportion of respondents treated with morphine 4mg-buprenorphine 0.12mg, morphine 6mg-buprenorphine 0.18mg, morphine 12mg-buprenorphine 0.36mg, ketorolac and parecoxib was 44.21%; 44.21%; 46.42%; 63.64% and 71.76%, respectively. The expected cost per patient of morphine 4mg, buprenorphine 0.12mg, morphine 6mg, buprenorphine 0.18mg, morphine 12mg, buprenorphine 0.36mg, ketorolac and parecoxib was $4.53; $1.45; $6.32; $1.71; $11.69; $2.48; $0.84 and $7.12, respectively. All the alternatives (except parecoxib, ICER: $77.30) are dominated by ketorolac. Furthermore, parecoxib is more effective than competing alternatives but only less expensive than morphine 12mg. CONCLUSIONS: At IMSS setting, parecoxib appears to be cost-saving regarding morphine 12mg and cost-effective regarding ketorolac, buprenorphine and morphine 4 and 6mg.

Conference/Value in Health Info

2012-06, ISPOR 2012, Washington, D.C., USA

Value in Health, Vol. 15, No. 4 (June 2012)

Code

PSY32

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Systemic Disorders/Conditions

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×